Modulating cell-free DNA biology as the next frontier in liquid biopsies
- PMID: 39730275
- PMCID: PMC12145268
- DOI: 10.1016/j.tcb.2024.11.007
Modulating cell-free DNA biology as the next frontier in liquid biopsies
Abstract
Technical advances over the past two decades have enabled robust detection of cell-free DNA (cfDNA) in biological samples. Yet, higher clinical sensitivity is required to realize the full potential of liquid biopsies. This opinion article argues that to overcome current limitations, the abundance of informative cfDNA molecules - such as circulating tumor DNA (ctDNA) - collected in a sample needs to increase. To accomplish this, new methods to modulate the biological processes that govern cfDNA production, trafficking, and clearance in the body are needed, informed by a deeper understanding of cfDNA biology. Successful development of such methods could enable a major leap in the performance of liquid biopsies and vastly expand their utility across the spectrum of clinical care.
Keywords: biomarkers; cfDNA clearance; cfDNA shedding; ctDNA.
Copyright © 2024 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests The authors are listed as inventors on a patent related to improving cfDNA recovery (PCT/US2022/013769). J.C.L., V.A.A., and S.N.B. are cofounders of Amplifyer Bio. C.M.A. is an employee of Amplifyer Bio. J.C.L. has interests in Sunflower Therapeutics PBC, Honeycomb Biotechnologies, OneCyte Biotechnologies, QuantumCyte, and Repligen, which were not involved in this work. V.A.A. is a coinventor on a patent application (US 2023/0203568, pending) licensed to Exact Sciences and receives research funding from Exact Sciences. S.N.B. reports consulting roles and/or equity in Sunbird Bio, Satellite Bio, Catalio Capital, Port Therapeutics, Matrisome Bio, Xilio Therapeutics, Ochre Bio, Vertex Pharmaceuticals, Ropirio Therapeutics, Danaher, and Owlstone Medical, which were not involved in this work. J.C.L.’s and S.N.B.’s interests were reviewed and managed under MIT’s policies for potential conflicts of interest.
Similar articles
-
Circulating tumor DNA in liquid biopsy: Current diagnostic limitation.World J Gastroenterol. 2024 Apr 21;30(15):2175-2178. doi: 10.3748/wjg.v30.i15.2175. World J Gastroenterol. 2024. PMID: 38681986 Free PMC article.
-
The Diagnostic Utility of cfDNA and ctDNA in Liquid Biopsies for Gastrointestinal Cancers over the Last Decade.Oncol Res Treat. 2025;48(3):125-141. doi: 10.1159/000543030. Epub 2024 Dec 16. Oncol Res Treat. 2025. PMID: 39681095 Review.
-
Computational Modeling for Circulating Cell-Free DNA in Clinical Oncology.JCO Clin Cancer Inform. 2025 Mar;9:e2400224. doi: 10.1200/CCI-24-00224. Epub 2025 Feb 28. JCO Clin Cancer Inform. 2025. PMID: 40020203 Review.
-
Priming agents transiently reduce the clearance of cell-free DNA to improve liquid biopsies.Science. 2024 Jan 19;383(6680):eadf2341. doi: 10.1126/science.adf2341. Epub 2024 Jan 19. Science. 2024. PMID: 38236959 Free PMC article.
-
Cell-free and extrachromosomal DNA profiling of small cell lung cancer.Trends Mol Med. 2025 Jan;31(1):64-78. doi: 10.1016/j.molmed.2024.08.004. Epub 2024 Sep 4. Trends Mol Med. 2025. PMID: 39232927 Review.
Cited by
-
Salivary cell-free DNA methylation analysis for oncological monitoring of surgical resection of oral squamous cell carcinoma.Front Oral Health. 2025 Jun 11;6:1614371. doi: 10.3389/froh.2025.1614371. eCollection 2025. Front Oral Health. 2025. PMID: 40567599 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous